Abstract

Background: Triple-negative breast cancer (TNBC) is a special subtype of breast cancer with poor prognosis. DNA damage response (DDR) is one of the hallmarks of this cancer. However, the association of DDR genes with the prognosis of TNBC is still unclear.Methods: We identified differentially expressed genes (DEGs) between normal and TNBC samples from The Cancer Genome Atlas (TCGA). DDR genes were obtained from the Molecular Signatures Database through six DDR gene sets. After the expression of six differential genes were verified by quantitative real-time polymerase chain reaction (qRT-PCR), we then overlapped the DEGs with DDR genes. Based on univariate and LASSO Cox regression analyses, a prognostic model was constructed to predict overall survival (OS). Kaplan–Meier analysis and receiver operating characteristic curve were used to assess the performance of the prognostic model. Cox regression analysis was applied to identify independent prognostic factors in TNBC. The Human Protein Atlas was used to study the immunohistochemical data of six DEGs. The prognostic model was validated using an independent dataset. Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes analysis were performed by using gene set enrichment analysis (GSEA). Single-sample gene set enrichment analysis was employed to estimate immune cells related to this prognostic model. Finally, we constructed a transcriptional factor (TF) network and a competing endogenous RNA regulatory network.Results: Twenty-three differentially expressed DDR genes were detected between TNBC and normal samples. The six-gene prognostic model we developed was shown to be related to OS in TNBC using univariate and LASSO Cox regression analyses. All the six DEGs were identified as significantly up-regulated in the tumor samples compared to the normal samples in qRT-PCR. The GSEA analysis indicated that the genes in the high-risk group were mainly correlated with leukocyte migration, cytokine interaction, oxidative phosphorylation, autoimmune diseases, and coagulation cascade. The mutation data revealed the mutated genes were different. The gene-TF regulatory network showed that Replication Factor C subunit 4 occupied the dominant position.Conclusion: We identified six gene markers related to DDR, which can predict prognosis and serve as an independent biomarker for TNBC patients.

Highlights

  • Breast cancer is the most common malignancy in women

  • Following analysis of the The Cancer Genome Atlas (TCGA) database using limma, a total of 2,178 Differentially expressed genes (DEGs) were identified in 113 Triple-negative breast cancer (TNBC) and 99 normal samples (| log2| > 1, P < 0.05)

  • DE-DNA damage response (DDR) was performed by the R package

Read more

Summary

Introduction

Breast cancer is the most common malignancy in women. The International Agency for Research on Cancer of the World Health Organization reported that the number of new cases of breast cancer reached 2.26 million in 2020, and breast cancer has become the most prevalent malignant tumor in the world (Sung et al, 2021). Breast cancer is a biologically and clinically heterogeneous disease with several recognized tissue and molecular subtypes with different etiologies, risk factors, treatment responses, and prognoses (Allemani et al, 2018; Mavaddat et al, 2019; Pashayan et al, 2020). Compared with other breast cancer subtypes, TNBC is highly aggressive and has a high rate of early recurrence. Due to the lack of ER, PR, and HER2 expression in TNBC tumors, few therapies targeting specific molecular targets have been able to significantly improve the prognosis of patients with TNBC disease, and chemotherapy remains the standard of treatment of TNBC (Bianchini et al, 2016; Lee et al, 2020). Triple-negative breast cancer (TNBC) is a special subtype of breast cancer with poor prognosis. The association of DDR genes with the prognosis of TNBC is still unclear

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call